Salvarx Share Discussion Threads

[the stigologist] 12/7/2018 10:24

Melting up on no news

Extraordinary

[the stigologist] 11/7/2018 16:17

very underowned i guess

[the stigologist] 11/7/2018 11:09

Post results road show? Liquidity event coming ?

[the stigologist] 11/7/2018 01:20

Just melting up on the sly

[the stigologist] 01/7/2018 11:51

Outlook

The main objective when we started this Company was to identify drugs/products that had interesting science behind them and that could benefit from our drug development and commercialization expertise. We have now been successful in sourcing a wide range of products from around the globe. Each has specific needs and challenges that our extended team has been focused on resolving. Not everything will go as planned, but the team has many years of experience in overcoming challenges, and finding creative solutions to push the programs forward.

The real reward is trying to help give hope to cancer patients for whom the available drugs have failed and are in need of new options. I am reminded of how challenging this is as one of our investigators writes to me about a woman in her 30s with no other options who is eager to get into one of our trials. The investor community is also optimistic about this sector with record amounts of venture money flowing into startups this past year. In fact, in February 2018, BMS recorded the largest upfront payment for a license in history. They paid US$3.6 billion for 35% of the profits on Nektar's immunotherapy after seeing data on approximately 40 patients.

At the SalvaRx corporate level, we continue to identify potential investments or acquisitions. We expect to grow further by acquisition, investment or licensing arrangements as we identify novel cancer immunotherapies. Not all of our projects will progress, as we are continually prioritizing those with the highest probability of success.

Dr lan Walters

Chief Executive Officer

27 June 2018

[the stigologist] 01/7/2018 11:51

breaking out

Golden Cross

[fillipe] 27/6/2018 16:20

Amazing....+ almost 14% and all that on really quite small.
Heaven only knows what the lift-up will be when the volume is really turned up.

30.6% at the lowest ask on show.

Happy days!

f

[fig1] 05/5/2018 14:38

Satisfactory end to the week.

[wiseacre] 03/5/2018 09:15

No liquidity in the shares. Won't take much buying to get the price above 30p where it should be.

[fig1] 02/5/2018 13:46

Patience Fillipe, patience.

[fillipe] 02/5/2018 13:41

SALV + 18% today, although seems to have dropped off the radars of most folks.

f

[kristini2] 09/4/2018 18:21

Aren't immunotherapy related stocks out of favour right now- given some recent failings in the immunotherapy related process and sector ?

[wiseacre] 05/4/2018 17:17

Actually dexdringle I think the stock is grossly undervalued but as far as the company is concerned it appears not to give a button, in terms of promotion here, and I have heard the American CEO, not only has a contempt for AIM, but, is looking to get the shares quoted his side of the Atlantic where biotech gets a better rating. With regard to my comment on the quality of investors I hardly think the promoter of the company at IPO, Peterhouse, has a great roster of long-term investors to get the stock away. Maybe you are one of them! No offence intended.

[dexdringle] 04/4/2018 15:39

"wiseacre 22 Mar '18 - 11:22 - 111 of 112

The problem is that those who subscribed at 33p, not the highest quality of investor......."

Eh ? Why would investing at 33p not been a sign of being a high quality investor ?

Presumably you were a genius and were shorting it from there (and are still doing so) thus making you a very high quality investor ?

Unless all investors who buy something that goes down are poor quality investors - in which case please stand up the person who only ever buys things that go up !!

[kristini2] 22/3/2018 16:41

well they could, but i'm rather disillusioned with riskier and small cap investing

I think you;re better off going to a casino

[wiseacre] 22/3/2018 11:22

The problem is that those who subscribed at 33p, not the highest quality of investor, have lost heart and there could be some tax loss selling, not to mention the fact that the shares have fallen on very low volume. I think Kristin's time horizon is far too pessimistic and the shares could easily double in the blink of an eye.

[kristini2] 20/3/2018 18:38

It's fairly illiquid with little volumes period, and so one must be prepared to hold long term, i mean maybe 5 years + I am thinking maybe 10 years

It will not take too much given the market cap here to see positive price action, and so the risk reward over 5 years looks good. The speculative nature is a given

[dexdringle] 20/3/2018 16:25

Good point.

What I don't understand is why the price peaked at 45p and is now 20p (ish). surely there are not sufficient fickle holders to cause the price to fall and fall. Most must be in it for the long haul. So why the volatility ?

[wiseacre] 20/3/2018 16:20

Come on dexdringle you should know that biotech has long lead times but with cancer immunotherapy lead times are quicker. If you have no patience you shouldn't be here.

[dexdringle] 19/3/2018 15:01

....if they could be so kind as to see their way, if it isn't too much trouble, to start MAKING SOME IMPRESSIVE PROFITS then I suspect that we all might become a little more 'enchanted'.......

[wiseacre] 19/3/2018 10:46

The American management is disenchanted with AIM and, I believe, could be looking at a listing their side of the Atlantic

[the stigologist] 15/3/2018 23:41

Yep I don't think I'd invest just on Mellon
The American angle more interesting

[wiseacre] 15/3/2018 17:42

You are quite right Stig but this one is led by an American who came out of Bristol Myers Squibb, the leaders in immunotherapy, and has done zilch PR for the company. The company was floated at 33p two years ago and has come a long way since then. Time will tell.

[blueball] 15/3/2018 16:43

Kumo bull break-out today.

[the stigologist] 15/3/2018 10:20

maybe it's a good shout on Mellon but I don't think he's regarded as being that good that people would just buy his tips just because he's tipped something

he is a bit hit and miss and often times on public listed stuff miss